Ocrevus (ocrelizumab) and Tysabri (natalizumab) appear equally effective at controlling relapses and MS progression, a study ...
The makers of Tysabri have filed new safety data and revised labeling with the FDA in a bid to reinstate the multiple sclerosis drug by next March. Biogen Idec and Elan asked for a priority review, ...
An FDA advisory panel ruled unanimously today that Biogen Idec’s multiple sclerosis drug Tysabri should return to the market with safeguards to monitor patient complications.The FDA advisory panel ...
Today, (NASDAQ: BIIB) and , plc (NYSE: ELN) announced that results from 11 company-sponsored TYSABRI presentations, including 10 posters and one platform, will be available for viewing at the 28 ...
Add Yahoo as a preferred source to see more of our stories on Google. The National Institute for Health and Care Excellence (NICE) has recommended natalizumab as an option for adults with highly ...
Tysabri (natalizumab) helps treat forms of multiple sclerosis and Crohn’s disease. The drug comes as an infusion solution. Tysabri is not safe to receive in pregnancy and may not be safe to receive ...
* Perrigo company plc - deal includes up to $650 million in potential milestone payments based upon future global net sales of tysabri in 2018 and 2020 * Perrigo company plc - transaction is valued at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results